Clareo Health | Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
H. Lundbeck A/S
Age
5–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
5 to 17 year of age or turned 18 while enrolled in the 331-201-00148 study
Autism Spectrum Disorder
Completion of 331-201-00148 trial
Investigator assessment
You may not be if
Did not complete treatment period or incurred significant protocol deviations during 331-201-00148 study
Sexually active males or female of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose
